Edition:
United States

Oxford BioMedica PLC (OXB.L)

OXB.L on London Stock Exchange

4.08GBp
22 Jul 2016
Change (% chg)

-0.01p (-0.24%)
Prev Close
4.09p
Open
4.10p
Day's High
4.30p
Day's Low
4.00p
Volume
2,754,171
Avg. Vol
2,346,709
52-wk High
10.00p
52-wk Low
3.65p

Latest Key Developments (Source: Significant Developments)

Oxford Biomedica says Chief Development Officer Blake to leave in Aug
Thursday, 12 May 2016 02:11am EDT 

Oxford Biomedica Plc : Announces that Dr Paul Blake will leave group when his current contract expires at end of August 2016. .Blake was appointed to Oxford Biomedica's board as a non-executive director in January 2010 and subsequently he became chief development officer in September 2014..  Full Article

Oxford Biomedica PLC secures $50 million loan with oberland capital
Friday, 1 May 2015 02:00am EDT 

Oxford Biomedica PLC:Says that it has secured a $50 million loan facility from a subsidiary of Oberland Capital Healthcare.The funds will be used to invest in the Group's capacity expansion to enable it to deliver on commitments under its manufacturing agreement with Novartis and for pipeline advancements and product acquisitions.  Full Article

Oxford Biomedica acquires Windrush Court Office
Monday, 13 Oct 2014 02:00am EDT 

Oxford Biomedica PLC:Says that it has acquired freehold of Windrush Court office and laboratory facilities in Transport Way, Oxford, England.Says for total cash consideration of 3.2 mln pounds from Oxford Real Estate Owner No. 2 Limited.Windrush Court, 6,684 sq m facility, is located directly opposite Oxford BioMedica's manufacturing facility and company intends to relocate its laboratories and office activities there in stages before current lease of Medawar Centre, Oxford expires in March 2016.The purchase of Windrush Court will enable company to consolidate its entire activities in Transport Way, improving operational effectiveness, and will also provide additional capacity to accommodate planned growth in business activities.As result of expected savings in rental costs and service charges, Oxford BioMedica expects to recover purchase cost within 4 years.  Full Article

Oxford Biomedica PLC announces second major agreement with Novartis
Friday, 10 Oct 2014 02:00am EDT 

Oxford Biomedica PLC:Signs further contracts with Novartis which build on collaboration with Novartis announced in May 2013.Under terms of new agreement, Novartis will pay $14 mln upfront including $4.3 mln equity subscription for non-exclusive worldwide development and commercialisation licence in oncology under Group's LentiVector platform.OXB will manufacture lentiviral vectors expressing CTL019/CART-019.Manufacturing contract has an initial three year term.Additionally, OXB has granted Novartis an exclusive licence for worldwide development and commercialisation of all Chimeric Antigen Receptor (CAR) T cell products arising from the process development collaboration.  Full Article

BRIEF-Oxford BioMedica grants to MolMed non-exclusive licence under its LentiVector platform technology

* Signs with Oxford BioMedica new non-exclusive licence agreement concerning lentiviral vector technology